Gibson, Dunn & Crutcher LLP has advised North Immunology, Inc. North Immunology, Inc. and Aethlon Medical, Inc. (Nasdaq: AEMD) have entered into a definitive merger agreement...
North Immunology and Aethlon Medical Announce $346.5 Million Merger and $180 Million Private Placement
Avere Therapeutics Secures $500 Million in Private Placement for Development of Once-Weekly Oral IL-23 Therapy
Gibson Dunn has advised Avere Therapeutics. Cooley has advised the placement agents. Avere Therapeutics, Inc. (“Avere”), a privately-held biotechnology company, has announced a $500 million private...
Neurogene Completes $143.7 Million Public Offering of Shares and Pre-Funded Warrants
Gibson Dunn has advised Neurogene Inc. Cooley LLP has advised the underwriters. Foley Hoag LLP has served as special counsel to Neurogene Inc. with respect to...
Avere Therapeutics and NextCure Announce Merger with $320 Million Private Placement
Gibson Dunn has advised Avere Therapeutics. Sidley Austin has advised NextCure. Avere Therapeutics, Inc., a privately-held biotechnology company, and NextCure, Inc. (Nasdaq:NXTC), a clinical-stage biopharmaceutical company,...
MoonLake Immunotherapeutics Completes $200 Million Public Offering of Class A Shares
Gibson, Dunn & Crutcher LLP and Walkers (Cayman) LLP have advised MoonLake Immunotherapeutics. Mintz has advised the underwriters. MoonLake Immunotherapeutics (NASDAQ: MLTX) has completed a public...
Serapha Bio and Boundless Bio Announce Merger and $230 Million Private Placement
Gibson Dunn has advised Serapha Bio, Inc. Latham & Watkins has advised Boundless Bio, Inc. Serapha Bio, Inc., a privately held biotechnology company, and Boundless Bio,...
Quince Therapeutics Acquires OrphAI Therapeutics for $80.9 Million and Executes Concurrent Private Placement
Gibson Dunn has advised LifeSci Capital as financial advisor to Quince Therapeutics. Cooley has advised Orphai Therapeutics. Quince Therapeutics, Inc. has completed its acquisition of OrphAI...
InMed Pharmaceuticals and Mentari Therapeutics Announce Merger and US$290 Million Private Placement to Accelerate Migraine Therapies
Gibson, Dunn & Crutcher LLP has advised Mentari Therapeutics, Inc. Norton Rose Fulbright LLP and Norton Rose Fulbright Canada LLP have advised InMed Pharmaceuticals, Inc. InMed...
Assertio Holdings to be Acquired by Zydus Worldwide DMCC in $166 Million All-Cash Deal
Gibson, Dunn & Crutcher LLP has advised Assertio Holdings, Inc. Assertio Holdings, Inc. (Nasdaq: ASRT) has announced the approval of a definitive agreement under which it...
Cytokinetics Raises $805 Million in Public Offering of Common Stock
Gibson Dunn has advised Cytokinetics, Incorporated. Latham & Watkins LLP has advised the underwriters. Cytokinetics, Incorporated (Nasdaq: CYTK) completed a public offering of 11,338,028 shares of...
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
Paul Hastings LLP has advised Ligand Pharmaceuticals Incorporated. Gibson Dunn has advised XOMA Royalty Corporation. Ligand Pharmaceuticals Incorporated has entered into a definitive agreement to acquire...
Assertio to Be Acquired by Garda Therapeutics in $125.1 Million All-Cash Deal
Gibson, Dunn & Crutcher LLP has advised Assertio Holdings, Inc. Assertio Holdings, Inc. (ASRT) has entered into a definitive agreement to be acquired by Garda Therapeutics....